KONINKLIJKE DSM N.V. Inactive Instrument
Koninklijke DSM N.V. Stock Other OTC
Equities
RDSMY
US7802491081
Consumer Goods Conglomerates
| Sales 2024 * | 12.6B 13.5B 18.47B | Sales 2025 * | 13.27B 14.22B 19.45B | Capitalization | 28.01B 30.01B 41.05B |
|---|---|---|---|---|---|
| Net income 2024 * | 459M 492M 673M | Net income 2025 * | 795M 852M 1.16B | EV / Sales 2024 * | 2.45 x |
| Net Debt 2024 * | 2.84B 3.04B 4.16B | Net Debt 2025 * | 2.57B 2.75B 3.76B | EV / Sales 2025 * | 2.3 x |
| P/E ratio 2024 * |
61
x | P/E ratio 2025 * |
35.2
x | Employees | - |
| Yield 2024 * |
2.38% | Yield 2025 * |
2.34% | Free-Float | 25.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Koninklijke DSM N.V.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 89-12-31 | |
Ralf Schmeitz
DFI | Director of Finance/CFO | - | 23-08-31 |
Sarah Reisinger
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 23-01-31 | |
Thomas Leysen
CHM | Chairman | 63 | 23-01-31 |
| Director/Board Member | 62 | 23-01-31 |
DSM-Firmenich AG is a leading innovator in nutrition, health, and beauty. It reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With a comprehensive range of natural and renewable ingredients and renowned science and technology capabilities, the company uniquely works to create what is essential for life, desirable for consumers, and more sustainable for the planet.
Sector
Consumer Goods Conglomerates
Calendar
2024-07-30
- Q2 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +12.83% | 881B | |
| +2.13% | 243B | |
| +24.56% | 176B | |
| +1.83% | 140B | |
| -9.54% | 70.84B | |
| -6.52% | 57.09B | |
| +109.08% | 35.76B | |
| -37.23% | 32.94B | |
| +28.44% | 32.6B |
